A pivotal Phase 3 clinical study of MDR-101 in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

Trial Profile

A pivotal Phase 3 clinical study of MDR-101 in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

Planning
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs MDR 101 (Primary)
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Medeor Therapeutics
  • Most Recent Events

    • 10 May 2017 New trial record
    • 28 Apr 2017 According to a Medeor Therapeutics media release, the company has received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for the company's lead product candidate MDR-101. In addition, the FDA has agreed to a Special Protocol Assessment (SPA) for the design of a pivotal Phase III clinical study of MDR-101.
    • 28 Apr 2017 According to a Medeor Therapeutics media release, company plans to initiate this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top